ORION CORPORATION STOCK EXCHANGE RELEASE 22 SEPTEMBER 2014 at 6.20 p.m.
EEST
Orion announces amended settlement agreement over the proprietary drug Precedex®
Orion Corporation ("Orion") together with Hospira, Inc. ("Hospira") and Sandoz
Inc. and Sandoz Canada Inc. (hereinafter collectively "Sandoz") have amended the
settlement agreement published on 5 December 2013 regarding the market entry of
Sandoz in the United States with generic version of Orion's Precedex® product.
The settlement agreement has been amended so that Sandoz may launch generic
version of Precedex® in the United States immediately.
The other terms and conditions of the settlement agreement are confidential.
In compliance with the applicable U.S. laws, the above agreement will be filed
with the United States Federal Trade Commission and the United States Department
of Justice.
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions
Contact person:
Olli Huotari, SVP, Corporate Functions
tel. +358 10 426 3054
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2013 amounted to EUR 1,007 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
[HUG#1855316]